Mutations and amplifications in ErbB receptors are common in various cancers. For example:
- EGFR Mutations: Mutations in the EGFR gene are frequently observed in non-small cell lung cancer (NSCLC). These mutations often result in constitutive activation of the receptor, independent of ligand binding. - HER2 Amplification: HER2 gene amplification is a hallmark of certain types of breast cancer and is associated with poor prognosis. It leads to overexpression of the HER2 protein, promoting aggressive tumor growth. - HER3 and HER4 Alterations: While less common, alterations in HER3 and HER4 can also contribute to cancer development, often through forming heterodimers with other ErbB family members.
